tbuckley/cabot-search huggingface dataset:
457P Background of patients (pts) with ALK rearranged (ALK+) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
Authors: K. Ito, H. Saiki, T. Sakaguchi, K. Hayashi, Y. Nishii, F. Watanabe, O. Hataji, T. Okano, M. Naito, H. Ibata, A. Fujiwara, M. Yoshida, H. Itani, M. Tanigawa, H. Kobayashi
Journal: Annals of Oncology (2015)
Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease
Authors: Fusheng Zhou, Hongzhi Cao, Xianbo Zuo, Tao Zhang, Xiaoguang Zhang, Xiaomin Liu, Ricong Xu, Gang Chen, Yuanwei Zhang, Xiaodong Zheng, Xin Jin, Jinping Gao, Junpu Mei, Yujun Sheng, Qibin Li, Bo Liang, Juan Shen, Changbing Shen, Hui Jiang, Caihong Zhu, Xing Fan, Fengping Xu, Min Yue, Xianyong Yin, Chen Ye, Cuicui Zhang, Xiao Liu, Liang Yu, Jinghua Wu, Mengyun Chen, Xuehan Zhuang, Lili Tang, Haojing Shao, Longmao Wu, Jian Li, Yu Xu, Yijie Zhang, Suli Zhao, Yu Wang, Ge Li, Hanshi Xu, Lei Zeng, Jianan Wang, Mingzhou Bai, Yanling Chen, Wei Chen, Tian Kang, Yanyan Wu, Xun Xu, Zhengwei Zhu, Yong Cui, Zaixing Wang, Chunjun Yang, Peiguang Wang, Leihong Xiang, Xiang Chen, Anping Zhang, Xinghua Gao, Furen Zhang, Jinhua Xu, Min Zheng, Jie Zheng, Jianzhong Zhang, Xueqing Yu, Yingrui Li, Sen Yang, Huanming Yang, Jian Wang, Jianjun Liu, Lennart Hammarström, Liangdan Sun, Jun Wang, Xuejun Zhang
Journal: Nature Genetics (2016)
Abstract P1-10-25: Intrathoracic paclitaxel chemotherapy for malignant pleural effusion in breast cancer
Authors: KJ Yeu, J Park, JE Choi, SH Kang, SJ Lee
Journal: Cancer Research (2016)

Abstract Background: Malignant pleural effusion in breast cancer has been associated with poor prognosis which median survival rate is 5–16 months. The response rate of local treatment has been very low and in some case, complications have resulted in death. Patients and methods: We investigated the efficacy and safety of paclitaxel, as an intrapleural chemotherapeutic agent. From January 2006 to June 2015, total 35 times of intrapleural chemothepapy were performed in 26 breast cancer patients who had developed malignant pleural effusion. They were infused 120mg/m2 of paclitaxel through a chest tube, which was clamped for 48 hours. The chest tube was maintained until drainage was reduced to less than 50-100 mL/day. Results: Mean follow up period after intrapleural chemotherapy was 11 months.The average time of indwelling with a chest tube after intrapleural chemotherapy was 9.7 days. Mean progression free survival was 7.8 Months. During the follow-up period, 5 patients had no progression of pleural effusion and 2 of them were free from progression for more than 36 months. In 26 attempts, there were effective and could remove chest tube otherwise In 9 attempts, there were no improvement after intrapleural chemotherapy. 1 patients received a second round of ipsilateral intrapleural chemotherapy and had no response unlike earlier attempts. There were 3 severe adverse effect related death caused by respiratory failure with or without G4 neutropenia. Conclusion: Intrapleural paclitaxel chemotherapy is helpful for some cases of uncontrolled pleural effusion in that reduce the duration of hospital stay and improve quality of life. But it will be determined carefully, considering the side effects and response rate of treatment. Citation Format: Yeu KJ, Park J, Choi JE, Kang SH, Lee SJ. Intrathoracic paclitaxel chemotherapy for malignant pleural effusion in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-25.
Goddess Night
Authors: Ann R Garment
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Asthma-like Features and Clinical Course of Chronic Obstructive Pulmonary Disease. An Analysis from the Hokkaido COPD Cohort Study
Authors: Masaru Suzuki, Hironi Makita, Satoshi Konno, Kaoruko Shimizu, Hiroki Kimura, Hirokazu Kimura, Masaharu Nishimura
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Some patients with chronic obstructive pulmonary disease (COPD) have asthma-like features, such as significant bronchodilator reversibility, blood eosinophilia, and/or atopy, even if they are not clinically diagnosed as having asthma. However, the clinical significance of asthma-like features overlapping with COPD remains unclear.The aim of this study was to assess the effect of asthma-like features on the clinical course of patients with COPD who were adequately treated and followed-up over 10 years.A total of 268 patients with COPD who had been clinically considered as not having asthma by respiratory specialists were included in this study. The asthma-like features included in this study were bronchodilator reversibility (ΔFEV1, ≥12% and ≥200 ml), blood eosinophilia (≥300 cells/μl), and atopy (positive specific IgE for any inhaled antigen). The annual changes in post-bronchodilator FEV1 and COPD exacerbations were monitored during the first 5 years, and mortality was followed during the entire 10 years of the study.Fifty-seven subjects (21%) had bronchodilator reversibility, 52 (19%) had blood eosinophilia, and 67 (25%) had atopy. Subjects with blood eosinophilia had significantly slower annual post-bronchodilator FEV1 decline; bronchodilator reversibility and atopy did not affect the annual post-bronchodilator FEV1 decline, and none of the asthma-like features was associated with development of COPD exacerbation. Even if subjects had two or more asthma-like features, they displayed annual post-bronchodilator FEV1 declines and exacerbation rates similar to those of subjects with one or zero asthma-like features, as well as a lower 10-year mortality rate (P = 0.02).The presence of asthma-like features was associated with better clinical course in patients with COPD receiving appropriate treatment.
When Is Intensive Care Treatment Futile in Patients with Organ Failure and End-Stage Liver Disease?
Authors: K.P. Lindvig, M. Thiele, V. Fuhrmann, W. Laleman, K. Roedl, L. Verbeke, K. Faber, T. Strøm, J. O’Beirne, P. Toft, A. Krag
Journal: Journal of Hepatology (2016)
Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Tatsuo Hata, Marco Dal Molin, Masaya Suenaga, Jun Yu, Meredith Pittman, Matthew Weiss, Marcia I. Canto, Christopher Wolfgang, Anne Marie Lennon, Ralph H. Hruban, Michael Goggins
Journal: Clinical Cancer Research (2016)

Pancreatic cysts frequently pose clinical dilemmas. On one hand, cysts with high-grade dysplasia offer opportunities for cure, on the other hand, those with low-grade dysplasia are easily over treated. Cyst fluid markers have the potential to improve the evaluation of these cysts. Because telomerase activity is commonly activated in malignant cells, we evaluated the diagnostic performance of cyst fluid telomerase activity measurements for predicting histologic grade.Telomerase activity was measured using telomerase repeat amplification with digital-droplet PCR in surgically aspirated cyst fluid samples from 219 patients who underwent pancreatic resection for a cystic lesion (184 discovery, 35 validation) and 36 patients who underwent endoscopic ultrasound fine-needle aspiration. Methodologic and clinical factors associated with telomerase activity were examined.Telomerase activity was reduced in samples that had undergone prior thawing. Among 119 samples not previously thawed, surgical cyst fluids from cystic neoplasms with high-grade dysplasia ± associated invasive cancer had higher telomerase activity [median (interquartile range), 1,158 (295.9-13,033)] copies/μL of cyst fluid than those without [19.74 (2.58-233.6) copies/μL; P < 0.001)]. Elevated cyst fluid telomerase activity had a diagnostic accuracy for invasive cancer/high-grade dysplasia of 88.1% (discovery), 88.6% (validation), and 88.2% (merged). Among cysts classified preoperatively as having "worrisome features," cyst fluid telomerase activity had high diagnostic performance (sensitivity 73.7%, specificity 90.6%, accuracy, 86.1%). In multivariate analysis, telomerase activity independently predicted the presence of invasive cancer/high-grade dysplasia.Cyst fluid telomerase activity can be a useful predictor of the neoplastic grade of pancreatic cysts. Clin Cancer Res; 22(20); 5141-51. ©2016 AACRSee related commentary by Allen et al., p. 4966.
Case 44-1993
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Peter A. Rice, Howard Kesselman
Journal: New England Journal of Medicine (1993)

Presentation of CaseA 39-year-old man was admitted to the hospital because of fever, diffuse arthralgia, and purpuric skin lesions.There was a history of intravenous drug abuse 20 years earlier, during which the patient contracted hepatitis, with jaundice for 1 month. He discontinued the practice soon thereafter. Five years before admission a physician informed the patient that he was a carrier of hepatitis B viral antigen and had thrombocytopenia. Several months before entry he was also told of the presence of antibodies to viral hepatitis C. Microscopical examination of a liver-biopsy specimen at another hospital showed chronic active hepatitis . . .
Five-Year Risk of Colorectal Neoplasia after Negative Colonoscopy
Authors: Hermann Brenner, Ulrike Haug, Michael Hoffmeister
Journal: New England Journal of Medicine (2008)

To the Editor: The rate of 1.3% for advanced adenoma detected approximately 5 years after a negative colonoscopy, is indeed low, as Imperiale et al. report (Sept. 18 issue).1 The rate for detection of any adenoma was 16.0%. What is striking is the low proportion of patients with advanced adenoma relative to the proportion of patients with any adenoma (8.1%). Numerous factors may have contributed to this low observed rate, including a low risk of this condition in the study population, low rates of detection by endoscopists, and low rates observed by pathologists. In the Study of Colonoscopy Utilization, an ancillary to the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, data from nine U.S. centers were tracked for 589 subjects with nonadenomatous findings on initial colonoscopy (494 subjects with hyperplastic polyps and 95 with no polyps), with repeat colonoscopy within 6 years.2 The rate of advanced adenoma was 4.4%, and the rate of any adenoma 20.5%. The risk of advanced adenoma was thus more than three times as high as that reported by Imperiale et al. Although there are limited followup data available for subjects with negative findings on the initial colonoscopy, the proportion of patients with advanced adenoma relative to the proportion with any adenoma in our study (21.5%) is more consistent with that seen in most colonoscopy cohorts.3-5 Robert E. Schoen, M.D., M.P.H.
β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function
Authors: Giuseppe Procino, Monica Carmosino, Serena Milano, Massimo Dal Monte, Giorgia Schena, Maria Mastrodonato, Andrea Gerbino, Paola Bagnoli, Maria Svelto
Journal: Kidney International (2016)

To date, the study of the sympathetic regulation of renal function has been restricted to the important contribution of β1- and β2-adrenergic receptors (ARs). Here we investigate the expression and the possible physiologic role of β3-adrenergic receptor (β3-AR) in mouse kidney. The β3-AR is expressed in most of the nephron segments that also express the type 2 vasopressin receptor (AVPR2), including the thick ascending limb and the cortical and outer medullary collecting duct. Ex vivo experiments in mouse kidney tubules showed that β3-AR stimulation with the selective agonist BRL37344 increased intracellular cAMP levels and promoted 2 key processes in the urine concentrating mechanism. These are accumulation of the water channel aquaporin 2 at the apical plasma membrane in the collecting duct and activation of the Na-K-2Cl symporter in the thick ascending limb. Both effects were prevented by the β3-AR antagonist L748,337 or by the protein kinase A inhibitor H89. Interestingly, genetic inactivation of β3-AR in mice was associated with significantly increased urine excretion of water, sodium, potassium, and chloride. Stimulation of β3-AR significantly reduced urine excretion of water and the same electrolytes. Moreover, BRL37344 promoted a potent antidiuretic effect in AVPR2-null mice. Thus, our findings are of potential physiologic importance as they uncover the antidiuretic effect of β3-AR stimulation in the kidney. Hence, β3-AR agonism might be useful to bypass AVPR2-inactivating mutations.
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.
Authors: Elisa Vicenzi, Patrizia Bagnarelli, Elena Santagostino, Silvia Ghezzi, Massimo Alfano, Marina S. Sinnone, Giovanna Fabio, Lucia Turchetto, Gianluca Moretti, Adriano Lazzarin, Alberto Mantovani, Pier Mannuccio Mannucci, Massimo Clementi, Alessandro Gringeri, Guido Poli
Journal: Blood (1997)
Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema
Authors: Robert C McDermid, Sean M Bagshaw
Journal: New England Journal of Medicine (2008)

estudado por alguns autores.Recentemente, a utilização da ventilação não-invasiva com dois níveis de pressão (BiPAP) vem sendo estudada nessa situação clínica; entretanto, os resultados são controversos.
Abstract P3-05-12: Combination of anti-progranulin (GP88/PGRN) antibody and letrozole inhibits tumor formation of letrozole resistant breast cancer cell lines
Authors: G Serrero, J Dong, B Yue, D Hicks, J Hayashi
Journal: Cancer Research (2016)

Abstract The 88 kDa glycoprotein GP88 (Progranulin, PCDGF, acrogranin) is the largest member of the granulin/epithelin family of growth modulators identified as a driver of tumorigenesis. GP88 (PGRN) was also shown to be overexpressed in invasive ductal carcinoma (IDC)whereas it was negative in benign tumors and normal mammry epithelial tissue, thereby establishing GP88 as a therapeutic and diagnostic target in breast cancer (BC). Our laboratory has developed validated tools to measure GP88 in tumor biopsies and biological fluids as well as blocking its action. WE showed that GP88 was secreted and detected in the serum of BC patients at an increased level when compared to healthy subjects. Pathological studies with 530 cases of ER+ IDC with clinical outcomes showed that GP88 tumor expression was an independent prognostic indicator of recurrence in early stage BC patients. Training study followed by an independent validation study demonstrated that high GP88 tissue expression (GP88 3+) was associated with a 4-fold increase in risk of recurrence at 5 years. A neutralizing anti-GP88 antibody AG1 was expressed in a high yield CHO cell line was developed. The present study examined the effect of AG1 in letrozole resistant cell line AGLetR developed by long term selection in letrozole supplemented medium. This cell line showed decreased letrozole responsiveness in vivo and therefore constituted an excellent model for investigating letrozole resistance in vitro as well as in vivo. Here we report the results of studies investigating the effect of various doses of AG1 on LetR tumor development in combination with letrozole for AGLetR. We show that treatment with AG1 (10 mg/kg i.p.) in combination with letrozole was efficient to maintain long term responsiveness and inhibit tumor growth. Letrozole alone (5mg/kg) was unable to inhibit tumor growth and showed a doubling of tumor volume. Interestingly, long term combination treatment lead to tumor regression and inhibited tumor growth. These data suggest that inhibiting GP88 could provide a novel and alternative therapeutic strategy for patients with resistance to anti-estrogen therapy, being tamoxifen or letrozole. This works is supported by 2R44CA124179, HHSN 261201200060C, and HHSN2612014400C from NCI. Citation Format: Serrero G, Dong J, Yue B, Hicks D, Hayashi J. Combination of anti-progranulin (GP88/PGRN) antibody and letrozole inhibits tumor formation of letrozole resistant breast cancer cell lines. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-05-12.
Abstract IA36: Signatures of mutational processes
Authors: Mike Stratton
Journal: Cancer Research (2016)

Abstract All cancers are caused by somatic mutations. However, the processes underlying the genesis of somatic mutations in human cancer are remarkably poorly understood. Recent large-scale cancer genome sequencing initiatives have provided us with new insights into these mutational processes through the mutational signatures they leave on the cancer genome. In this talk I will review the mutational signatures found across cancer and consider the underlying mutational processes that have been operative. Citation Format: Mike Stratton. Signatures of mutational processes. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr IA36.
Folate Transport and the Modulation of Antifolate Sensitivity in a Methotrexate-Resistant Human Breast Cancer Cell Line
Authors: Katharine H. Dixon, Jane B. Trepel, Simona C. Eng, Kenneth H. Cowan
Journal: Cancer Communications (1991)

The mechanism of acquired methotrexate-resistance in an estrogen-receptor positive human breast cancer cell line (MTX(R)ZR-75-1) was studied. MTX(R) ZR-75-1 cells are 250-fold resistant to methotrexate when grown in the presence of 1 microM folinic acid and 2,400-fold resistant in the presence of 1 microM folic acid. This drug resistant cell line also showed collateral sensitivity (10-fold) to trimetrexate (TMQ), when grown in the presence of folinic acid. Using fluoresceinated methotrexate (F-MTX), FACS analysis indicated that there is no intracellular accumulation of methotrexate into MTX(R) ZR-75-1 cells, as determined by competition of F-MTX and methotrexate binding to dihydrofolate reductase. These characteristics strongly indicate that the mechanism of resistance involved down regulation of the reduced-folate transporter. To investigate this further, the transport kinetics of parental and MTX(R) ZR-75-1 cells were examined. Although the V(max) for methotrexate transport in wild-type (WT) ZR-75-1 breast cancer cells was 1-2 orders of magnitude lower than that in the well characterized leukemia cell lines, such as L1210 and CCRF-CEM cells, kinetic analysis indicated that transport of methotrexate into WT ZR-75-1 cells involved a mechanism that was similar if not identical to the reduced folate transporter. In contrast, no specific uptake of methotrexate was detected in MTX(R) ZR-75-1cells. Furthermore, neither cell line expressed detectable levels of folate binding protein, a binding protein with high affinity for folic acid as well as for reduced folates and antifolates. These results indicate that the level of expression of the reduced-folate carrier may be an important factor in determining the sensitivity of breast cancer cells as well as leukemia cells to antifolate compounds.
Functions of PARylation in DNA Damage Repair Pathways
Authors: Huiting Wei, Xiaochun Yu
Journal: Genomics Proteomics & Bioinformatics (2016)

Abstract Protein poly ADP-ribosylation (PARylation) is a widespread post-translational modification at DNA lesions, which is catalyzed by poly(ADP-ribose) polymerases (PARPs). This modification regulates a number of biological processes including chromatin reorganization, DNA damage response (DDR), transcriptional regulation, apoptosis, and mitosis. PARP1, functioning as a DNA damage sensor, can be activated by DNA lesions, forming PAR chains that serve as a docking platform for DNA repair factors with high biochemical complexity. Here, we highlight molecular insights into PARylation recognition, the expanding role of PARylation in DDR pathways, and the functional interaction between PARylation and ubiquitination, which will offer us a better understanding of the biological roles of this unique post-translational modification.
Case 53-1966
Authors: Arnold N. Weinberg, Martin H. Flax
Journal: New England Journal of Medicine (1966)

Presentation of Case First admission. A forty-six-year-old man entered the hospital because of pain in the chest.Twenty years previously he was admitted to another hospital for study of migratory polyarthritis. Dental extractions were performed, and all the joint symptoms subsided within a month. He felt well after discharge and passed a physical examination by the Merchant Marine Service several years later. Seven months before admission he was refused a life insurance policy. Fourteen weeks before entry a mild sore throat and hoarseness developed. Ankle edema subsequently appeared, and a physician reported that the urine contained protein and numerous red . . .
Mandatory reporting of occupational diseases by clinicians
Authors: E Freund, P J Seligman, T L Chorba, S K Safford, J G Drachman, H F Hull
Journal: JAMA (1989)

OCCUPATIONAL disease surveillance is a critical step in the prevention of work-related injury and illness. 1 Case reporting by health care providers to public health authorities is one way of identifying sources of exposure toward which control measures can be directed. Most health care providers are familiar with the existence of reporting requirements for infectious diseases such as tuberculosis and the sexually transmitted diseases; however, less attention has been paid by the medical community to recognizing and reporting occupationally related conditions. 2,3   The Department of Labor estimated that in 1978 approximately 1.9 million people were severely or partially disabled from occupationally related diseases, at an annual cost of $11.4 billion in lost wages alone. 4 The Bureau of Labor Statistics reported an incidence of occupational injury and illness for 1984 of 8.0 cases and 63.4 lost workdays per 100 full-time workers. 5 This is most likely an underestimate, especially for
Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins
Authors: Pankaj Gupta, Theodore R. Oegema, Joseph J. Brazil, Arkaduisz Z. Dudek, Arne Slungaard, Catherine M. Verfaillie
Journal: Blood (2000)